CIBC Asset Management Inc Sells 27,055 Shares of Johnson & Johnson $JNJ

CIBC Asset Management Inc cut its position in Johnson & Johnson (NYSE:JNJ) by 3.6% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 724,290 shares of the company’s stock after selling 27,055 shares during the quarter. CIBC Asset Management Inc’s holdings in Johnson & Johnson were worth $134,267,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Clark Asset Management LLC grew its holdings in shares of Johnson & Johnson by 51.6% during the second quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock worth $1,357,000 after purchasing an additional 3,025 shares during the last quarter. Treasurer of the State of North Carolina raised its stake in Johnson & Johnson by 8.3% during the second quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock worth $188,638,000 after buying an additional 94,957 shares during the last quarter. Talbot Financial LLC raised its position in shares of Johnson & Johnson by 4.6% in the 3rd quarter. Talbot Financial LLC now owns 138,424 shares of the company’s stock worth $25,667,000 after acquiring an additional 6,143 shares in the last quarter. Liberty One Investment Management LLC increased its holdings in Johnson & Johnson by 83.9% in the third quarter. Liberty One Investment Management LLC now owns 366,813 shares of the company’s stock worth $68,040,000 after purchasing an additional 167,353 shares in the last quarter. Finally, Winnow Wealth LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at $295,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $221.54 on Tuesday. The company has a 50-day simple moving average of $208.79 and a two-hundred day simple moving average of $189.84. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $222.17. The firm has a market cap of $533.76 billion, a price-to-earnings ratio of 20.05, a PEG ratio of 2.14 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 21st. The company reported $2.46 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $2.46. The firm had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.34%. The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s payout ratio is currently 47.06%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on JNJ shares. Freedom Capital cut Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. Barclays upped their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Sunday. Guggenheim lifted their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a report on Friday. Finally, Argus lifted their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $226.18.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.